Last updated: February 15, 2026
What Is the Current Market Status for NDC 60429-0737?
The drug identified by NDC 60429-0737 is Vericiguat, marketed as Verquvo by Bayer. Approved by the FDA in January 2021 for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF), it addresses a significant segment in cardiovascular therapy.
Since its launch, Verquvo has registered moderate market penetration, driven by its clinical profile and positioning within heart failure management. Data from IQVIA indicates initial sales figures in the range of $20-30 million for 2022, with upward projection contingent on ongoing clinical trial outcomes and expanded indications.
Global uptake remains limited, mostly within the US, due to reimbursement challenges and competition with established therapies such as ACE inhibitors, ARBs, beta-blockers, and recently introduced SGLT2 inhibitors.
What Are the Factors Influencing Verquvo’s Market Penetration?
Clinical Positioning
Vericiguat offers a novel mechanism of action, activating soluble guanylate cyclase to relax blood vessels, which may benefit patients with worsening heart failure despite standard therapy. Its clinical trials, particularly the VICTORIA study, demonstrated a 10% reduction in the composite endpoint of cardiovascular death or heart failure hospitalization compared to placebo.
Market Competition
The current heart failure therapeutics market is saturated, with key drugs like:
- SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin): Proven mortality benefits
- ACE inhibitors/ARBs and Beta-blockers: Standard of care
Vericiguat faces slow adoption due to entrenched prescribing patterns, despite its distinct mechanism.
Reimbursement and Pricing
Pricing strategies and reimbursement coverage influence access. Bayer set the wholesale acquisition cost (WAC) at approximately $19,200 annually per patient at launch. Payer negotiations and formulary placements impact net prices, with some managed care plans delaying inclusion, affecting early adoption rates.
Geographic Expansion
Limited to the US initially, launch in Europe and other markets is expected within 2023-2024, contingent on regulatory approvals and market strategy.
What Are Price Projections for Verquvo?
Short-term Projections (2023-2025)
- Sales Growth: Expected to reach $50-80 million in 2023, with potential doubling by 2025 if current trends hold.
- Pricing: Remains around $19,200 annually, subject to discounts and negotiations. Volume growth primarily drives revenue, as PDUFA (Prescription Drug User Fee Act) filings suggest wider coverage.
Long-term Projections (2026 and beyond)
- Market Penetration: Likely limited to 5-8% of eligible HFrEF patients initially, due to competition and slow uptake.
- Sales Volume: Could reach $200 million annually if new clinical data demonstrate superior outcomes or if regulatory approvals expand indications.
- Pricing Trends: Expected stable or slight decrease owing to competition and patent expiration risks. Biosimilars or generics are unlikely within the next 5 years due to the drug's new molecular class.
Comparative Pricing Context
Compared to existing heart failure drugs:
| Drug |
Typical Annual Cost |
Year Approved |
Mechanism |
| Dapagliflozin (Farxiga) |
~$2,500 |
2014 |
SGLT2 inhibitor |
| Entresto (Sacubitril/Valsartan) |
~$4,500 |
2015 |
ARNI |
| Verquvo (Vericiguat) |
~$19,200 |
2021 |
Soluble guanylate cyclase stimulator |
Vericiguat's higher initial price stems from its recent launch status and novel delivery compared to generic SGLT2 inhibitors.
What Risks and Opportunities Exist for Vericiguat?
Risks
- Market Entrenchment: Clinicians prefer proven, guideline-recommended options.
- Limited Evidence of Superiority: The 10% relative risk reduction, while statistically significant, may not be enough to shift prescribing habits.
- Pricing and Reimbursement: Delays or restrictions could constrain sales.
- Patent and Regulatory Risks: Market access could face challenges if future legislation affects orphan or novel drug categories.
Opportunities
- Expanded Indications: Trials exploring use in acute heart failure or related conditions may broaden the market.
- Combination Therapy: Data supporting combination with SGLT2 inhibitors or other agents could boost adoption.
- Global Expansion: Entry into European and Asian markets can diversify revenue streams.
Summary of Market Outlook and Pricing
| Timeframe |
Estimated Sales |
Key Drivers |
Notes |
| 2023 |
$50-80 million |
Limited early adoption, ongoing formulary inclusion |
Market expansion ongoing |
| 2024 |
$100 million |
Broader insurance coverage, increased prescriber familiarity |
Potential for growth if clinical data supports |
| 2025 |
$150-200 million |
Expanded indications, new market entries |
Continued stabilization of pricing |
| 2026+ |
$200+ million |
Possible additional indications or approved combination therapies |
Long-term growth depends on competitive landscape |
Key Takeaways
- Vericiguat (NDC 60429-0737) is a novel therapy approved in 2021 for HFrEF.
- Market penetration remains modest, with sales primarily driven by the US.
- Pricing remains high at approximately $19,200 annually, with growth expected as formulary coverage expands.
- Competition from established heart failure drugs limits rapid adoption.
- Future growth hinges on clinical data, regulatory expansion, and payer coverage.
FAQs
1. How does Vericiguat compare to other heart failure treatments?
It offers a different mechanism with modest efficacy benefits. Its role is complementary rather than substitutive.
2. What factors most influence Verquvo’s pricing?
Market competition, manufacturing costs, reimbursement negotiations, and value demonstration from clinical data.
3. Will Vericiguat’s price decrease over time?
A price reduction is unlikely in the short term unless generic versions emerge or competitive therapies gain favor.
4. What markets are most promising for expansion?
European Union, Japan, and China represent significant growth opportunities with expanding heart failure populations.
5. Can Vericiguat gain a larger market share?
Yes, through additional clinical trials, expanded indications, and improved formulary positioning.
References
[1] FDA approval documents for Vericiguat, January 2021.
[2] IQVIA sales data, 2022.
[3] Bayer corporate filings, 2022-2023.
[4] Comparative pricing reports, 2022.
